Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine
L Adès, MA Sekeres, A Wolfromm, ML Teichman… - Leukemia research, 2013 - Elsevier
Treatment of CMML remains a clinical challenge, with no drug demonstrating clear clinical
benefit. Even if azacitidine is approved in the treatment of CMML, its role remains disputed.
We report a cohort of 76 CMML patients (according to WHO classification) treated with
azacitidine in 3 programs (French AZA compassionate program, Cleveland Clinic
Foundation and H. Lee Moffitt Cancer Center). 45% had CMML2, and 55% had
splenomegaly and/or WBC counts> 13G/L, which are known to be poor prognostic factors in …
benefit. Even if azacitidine is approved in the treatment of CMML, its role remains disputed.
We report a cohort of 76 CMML patients (according to WHO classification) treated with
azacitidine in 3 programs (French AZA compassionate program, Cleveland Clinic
Foundation and H. Lee Moffitt Cancer Center). 45% had CMML2, and 55% had
splenomegaly and/or WBC counts> 13G/L, which are known to be poor prognostic factors in …
